We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP37743
Poster Title: Implementation of Holistic Glycopeptide PASEF-DDA Data In Diagnostics
Submitted on 05 Oct 2021
Author(s): Hans JCT Wessels1, Purva Kulkarni1, Fokje Zijlstra1, Merel Post1, Melissa Bärenfänger1, Pierre-Olivier Schmit2, Alain J van Gool1, Dirk J Lefeber1
Affiliations: 1Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud university medical center, Nijmegen, the Netherlands; 2 Bruker Daltonique S.A., Wissembourg, France
Poster Views: 276
Submitted on 05 Oct 2021
Author(s): Hans JCT Wessels1, Purva Kulkarni1, Fokje Zijlstra1, Merel Post1, Melissa Bärenfänger1, Pierre-Olivier Schmit2, Alain J van Gool1, Dirk J Lefeber1
Affiliations: 1Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud university medical center, Nijmegen, the Netherlands; 2 Bruker Daltonique S.A., Wissembourg, France
Poster Views: 276
Abstract: • Holistic PASEF-DDA data is of sufficient quality for use in both biomarker research and diagnostics.
• Glycopeptide workflow for diagnosis of congenital disorders of glycosylation will be implemented in clinical care in 2021
• Use of real-time glycopeptide data processing and reporting by GPU-parallelisation will be explored for next generation workflowsSummary: Advantages of holistic PASEF-DDA data acquisition for clinical applications:
- Single data file can be used for both biomarker research and application
- All possible MS1 and MS/MS data is generated for each sample to enable retrospective analysis of novel biomarkers
- Different disease biomarkers can be evaluated by simply exchanging the glycosylation site targets used for targeted feature extraction
• Glycopeptide workflow for diagnosis of congenital disorders of glycosylation will be implemented in clinical care in 2021
• Use of real-time glycopeptide data processing and reporting by GPU-parallelisation will be explored for next generation workflowsSummary: Advantages of holistic PASEF-DDA data acquisition for clinical applications:
- Single data file can be used for both biomarker research and application
- All possible MS1 and MS/MS data is generated for each sample to enable retrospective analysis of novel biomarkers
- Different disease biomarkers can be evaluated by simply exchanging the glycosylation site targets used for targeted feature extraction
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Why Choose Untargeted Metabolomics?
Creative Proteomics
Lipidomics Research Methods
Creative Proteomics
Lipidomics and Bioinformatics Analysis
Creative Proteomics
Exosome Proteomics
Creative Proteomics
Untargeted Metabolomics
Creative Proteomics
